Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
Author:
Funder
National Institute of Diabetes and Digestive and Kidney Diseases
Leona M. and Harry B. Helmsley Charitable Trust
Pfizer
National Institutes of Health
Publisher
Elsevier BV
Reference100 articles.
1. A review of available medical therapies to treat moderate-to-severe inflammatory bowel disease;Chang;Am J Gastroenterol,2024
2. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis;Taxonera;Inflamm Bowel Dis,2022
3. 1-year comparison of clinical and endoscopic outcomes of tofacitinib vs vedolizumab for ulcerative colitis after anti-tumor necrosis factor failure: a real-world cohort study in the United States;Dalal;Inflamm Bowel Dis,2024
4. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent;Buisson;Aliment Pharmacol Ther,2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3